BI-765049

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameBI-765049
Drug Alias NameBI-765049OBT-624
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumoursStomach NeoplasmsColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesOxford Biotherapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgBoehringer Ingelheim International GmbhBoehringer Ingelheim (China) Investment Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursStomach NeoplasmsColorectal Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A